SARS-CoV-2 main protease inhibition by natural compounds

Area of Science:

• Drug discovery and development
• Virology
• Medicinal chemistry

Background:

• The COVID-19 pandemic highlighted the need for diverse therapeutic strategies beyond vaccines.
• Existing treatments like Paxlovid are available, but research continues for novel antiviral agents.
• The SARS-CoV-2 main protease is a critical target for inhibiting viral replication.

Purpose of the Study:

• To computationally screen natural compound libraries for potential inhibitors of the SARS-CoV-2 main protease.
• To identify novel lead compounds for COVID-19 therapeutic development.

Main Methods:

• Virtual screening of natural compound databases (Sigma-Aldrich, Molport).
• In silico identification of potential ligands targeting the SARS-CoV-2 main protease.
• In vitro confirmation of inhibitory activity using proteolytic assays.

Main Results:

• Three compounds (SID336241534, SID264573190, SID336181660) were identified as potential SARS-CoV-2 main protease inhibitors.
• In vitro assays confirmed the inhibitory activity of these identified compounds.
• These compounds serve as promising leads for further optimization.

Conclusions:

• Natural compounds represent a viable source for discovering new COVID-19 therapeutics.
• Identified compounds show potential as starting points for developing more potent protease inhibitors.
• Further in vivo and clinical studies are necessary to validate their therapeutic application.